New Non Invasive Test For Detection Of Tumors Of The Colon Is More Accurate Than Previously Used

New Non Invasive Test For Detection Of Tumors Of The Colon Is More Accurate Than Previously Used.
A additional noninvasive check-up to read pre-cancerous polyps and colon tumors appears to be more accurate than advised noninvasive tests such as the fecal occult blood test, Mayo clinic researchers say. The researching for a highly accurate, noninvasive alternative to invasive screens such as colonoscopy or sigmoidoscopy is a "Holy Grail" of colon cancer research. In a prior trial, the new try was able to identify 64 percent of pre-cancerous polyps and 85 percent of full-blown cancers, the researchers reported.

Dr Floriano Marchetti, an subordinate professor of clinical surgery in the division of colon and rectal surgery at University of Miami Sylvester Comprehensive Cancer Center, said the untrodden study could be an important adjunct to colon cancer screening if it proves itself in further study. "Obviously, these findings requisite to be replicated on a larger scale. Hopefully, this is a good start for a more reliable test".

Dr Durado Brooks, leader of colorectal cancer at the American Cancer Society, agreed. "These findings are interesting. They will be more fascinating if we ever get this kind of data in a screening population".

The study's lead researcher remained optimistic. "There are 150000 rejuvenated cases of colon cancer each year in the United States, treated at an estimated price of $14 billion," noted Dr David A Ahlquist, professor of c physic and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn. "The hallucinate is to eradicate colon cancer altogether and the most realistic approach to getting there is screening. And screening not only in a motion that would not only detect cancer, but pre-cancer. Our test takes us closer to that dream".

Ahlquist was scheduled to endowment the findings of the study Thursday in Philadelphia at a meeting on colorectal cancer sponsored by the American Association for Cancer Research. The redesigned technology, called the Cologuard sDNA test, innards by identifying specific altered DNA in cells shed by pre-cancerous or cancerous polyps into the patient's stool.

If a DNA distortion is found, a colonoscopy would still be needed to confirm the results, just as happens now after a unquestionable fecal occult blood test (FOBT) result. To see whether the test was effective, Ahlquist's group tried it out on more than 1100 frozen stool samples from patients with and without colorectal cancer.

The check was able to detect 85,3 percent of colorectal cancers and 63,8 percent of polyps bigger than 1 centimeter. Polyps this extent are considered pre-cancers and most likely to progress to cancer.